1 |
Kitami, S., Tanaka, H., Kawato, T., Tanabe, N., Katono-Tani, T., Zhang, F., Suzuki, N., Yonehara, Y. and Maeno, M. (2010) IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells. Biochimie 92, 398-404.
DOI
ScienceOn
|
2 |
Balani, D., Aeberli, D., Hofstetter, W. and Seitz, M. (2013) Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. Arthritis Rheum. 65, 436-446.
DOI
ScienceOn
|
3 |
Huang, W., La Russa, V., Alzoubi, A. and Schwarzenberger, P. (2006) Interleukin-17A: a T-cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells (Dayton, Ohio) 24, 1512-1518.
DOI
ScienceOn
|
4 |
Huang, H., Kim, H. J., Chang, E. J., Lee, Z. H., Hwang, S. J., Kim, H. M., Lee, Y. and Kim, H. H. (2009) IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell. Death. Differ. 16, 1332-1343.
DOI
ScienceOn
|
5 |
Nam, D., Mau, E., Wang, Y., Wright, D., Silkstone, D., Whetstone, H., Whyne, C. and Alman, B. (2012) T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair. PloS One 7, e40044.
DOI
|
6 |
Kocic, J., Santibanez, J. F., Krstic, A., Mojsilovic, S., Dordevic, I. O., Trivanovic, D., Ilic, V. and Bugarski, D. (2012) Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2. Biochim. Biophys. Acta. 1823, 838-849.
DOI
ScienceOn
|
7 |
Ahmed, M. and Gaffen, S. L. (2010) IL-17 in obesity and adipogenesis. Cytokine. Growth Factor Rev. 21, 449-453.
DOI
ScienceOn
|
8 |
Lubberts, E., Koenders, M. I., Oppers-Walgreen, B., van den Bersselaar, L., Coenen-de Roo, C. J., Joosten, L. A. and van den Berg, W. B. (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650-659.
DOI
ScienceOn
|
9 |
Koenders, M. I., Lubberts, E., Oppers-Walgreen, B., van den Bersselaar, L., Helsen, M. M., Di Padova, F. E., Boots, A. M., Gram, H., Joosten, L. A. and van den Berg, W. B. (2005) Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 167, 141-149.
DOI
ScienceOn
|
10 |
Koenders, M. I., Kolls, J. K., Oppers-Walgreen, B., van den Bersselaar, L., Joosten, L. A., Schurr, J. R., Schwarzenberger, P., van den Berg, W. B. and Lubberts, E. (2005) Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 52, 3239-3247.
DOI
ScienceOn
|
11 |
Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, P. and Sloan-Lancaster, J. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 62, 929-939.
DOI
ScienceOn
|
12 |
Koenders, M. I., Marijnissen, R. J., Joosten, L. A., Abdollahi-Roodsaz, S., Di Padova, F. E., van de Loo, F. A., Dulos, J., van den Berg, W. B. and Boots, A. M. (2012) T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum. 64, 1762-1770.
DOI
ScienceOn
|
13 |
Zwerina, K., Koenders, M., Hueber, A., Marijnissen, R. J., Baum, W., Heiland, G. R., Zaiss, M., McLnnes, I., Joosten, L., van den Berg, W., Zwerina, J. and Schett, G. (2012) Anti IL-17A therapy inhibits bone loss in TNF-alpha-mediated murine arthritis by modulation of the T-cell balance. Eur. J. Immunol. 42, 413-423.
DOI
ScienceOn
|
14 |
Bartold, P. M., Cantley, M. D. and Haynes, D. R. (2010) Mechanisms and control of pathologic bone loss in periodontitis. Periodontology 2000 53, 55-69.
DOI
ScienceOn
|
15 |
Chao, C. C., Chen, S. J., Adamopoulos, I. E., Davis, N., Hong, K., Vu, A., Kwan, S., Fayadat-Dilman, L., Asio, A. and Bowman, E. P. (2011) Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44, 243-252.
DOI
ScienceOn
|
16 |
Lubberts, E., van den Bersselaar, L., Oppers-Walgreen, B., Schwarzenberger, P., Coenen-de Roo, C. J., Kolls, J. K., Joosten, L. A. and van den Berg, W. B. (2003) IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J. Immunol. 170, 2655-2662.
DOI
|
17 |
Kikuta, J., Wada, Y., Kowada, T., Wang, Z., Sun-Wada, G. H., Nishiyama, I., Mizukami, S., Maiya, N., Yasuda, H., Kumanogoh, A., Kikuchi, K., Germain, R. N. and Ishii, M. (2013) Dynamic visualization of RANKL and Th17-mediated osteoclast function. J. Clin. Invest. 123, 866-873.
|
18 |
Oda, T., Yoshie, H. and Yamazaki, K. (2003) Porphyromonas gingivalis antigen preferentially stimulates T cells to express IL-17 but not receptor activator of NF-kappaB ligand in vitro. Oral Microbiol. Immunol. 18, 30-36.
DOI
ScienceOn
|
19 |
Takahashi, K., Azuma, T., Motohira, H., Kinane, D. F. and Kitetsu, S. (2005) The potential role of interleukin-17 in the immunopathology of periodontal disease. J. Clin. Periodentol. 32, 369-374.
DOI
ScienceOn
|
20 |
Vernal, R., Dutzan, N., Chaparro, A., Puente, J., Antonieta Valenzuela, M. and Gamonal, J. (2005) Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J. Clin. Periodontol. 32, 383-389.
DOI
ScienceOn
|
21 |
Adibrad, M., Deyhimi, P., Ganjalikhani Hakemi, M., Behfarnia, P., Shahabuei, M. and Rafiee, L. (2012) Signs of the presence of Th17 cells in chronic periodontal disease. J. Periodontal Res. 47, 525-531.
DOI
ScienceOn
|
22 |
Yu, J. J., Ruddy, M. J., Wong, G. C., Sfintescu, C., Baker, P. J., Smith, J. B., Evans, R. T. and Gaffen, S. L. (2007) An essential role for IL-17 in preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 109, 3794-3802.
DOI
ScienceOn
|
23 |
Schenkein, H. A., Koertge, T. E., Brooks, C. N., Sabatini, R., Purkall, D. E. and Tew, J. G. (2010) IL-17 in sera from patients with aggressive periodontitis. J. Dent. Res 89, 943-947.
DOI
ScienceOn
|
24 |
Duarte, P. M., da Rocha, M., Sampaio, E., Mestnik, M. J., Feres, M., Figueiredo, L. C., Bastos, M. F. and Faveri, M. (2010) Serum levels of cytokines in subjects with generalized chronic and aggressive periodontitis before and after non-surgical periodontal therapy: a pilot study. J. Periodontol. 81, 1056-1063.
DOI
ScienceOn
|
25 |
Kuestner, R. E., Taft, D. W., Haran, A., Brandt, C. S., Brender, T., Lum, K., Harder, B., Okada, S., Ostrander, C. D., Kreindler, J. L., Aujla, S. J., Reardon, B., Moore, M., Shea, P., Schreckhise, R., Bukowski, T. R., Presnell, S., Guerra-Lewis, P., Parrish-Novak, J., Ellsworth, J. L., Jaspers, S., Lewis, K. E., Appleby, M., Kolls, J. K., Rixon, M., West, J. W., Gao, Z. and Levin, S. D. (2007) Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J. Immunol. 179, 5462-5473.
DOI
|
26 |
Moseley, T. A., Haudenschild, D. R., Rose, L. and Reddi, A. H. (2003) Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14, 155-174.
DOI
ScienceOn
|
27 |
Rouvier, E., Luciani, M. F., Mattei, M. G., Denizot, F. and Golstein, P. (1993) CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 150, 5445-5456.
|
28 |
Witowski, J., Ksiazek, K. and Jorres, A. (2004) Interleukin-17: a mediator of inflammatory responses. Cell Mol. Life Sci. 61, 567-579.
DOI
ScienceOn
|
29 |
Korn, T., Bettelli, E., Oukka, M. and Kuchroo, V. K. (2009) IL-17 and Th17 Cells. Annu. Rev. Immunol. 27, 485-517.
DOI
ScienceOn
|
30 |
Yao, Z., Fanslow, W. C., Seldin, M. F., Rousseau, A. M., Painter, S. L., Comeau, M. R., Cohen, J. I. and Spriggs, M. K. (1995) Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3, 811-821.
DOI
ScienceOn
|
31 |
Toy, D., Kugler, D., Wolfson, M., Vanden Bos, T., Gurgel, J., Derry, J., Tocker, J. and Peschon, J. (2006) Cutting edge: interleukin 17 signals through a heteromeric receptor complex. J. Immunol. 177, 36-39.
DOI
|
32 |
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., Osterreicher, C. H., Stickel, F., Ley, K., Brenner, D. A. and Kisseleva, T. (2012) Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 143, 765-776.
DOI
ScienceOn
|
33 |
Gu, Y., Hu, X., Liu, C., Qv, X. and Xu, C. (2008) Interleukin (IL)-17 promotes macrophages to produce IL-8, IL-6 and tumour necrosis factor-alpha in aplastic anaemia. Br. J. Haematol. 142, 109-114.
DOI
ScienceOn
|
34 |
Mahanonda, R., Jitprasertwong, P., Sa-Ard-Iam, N., Rerkyen, P., Charatkulangkun, O., Jansisyanont, P., Nisapakultorn, K., Yongvanichit, K. and Pichyangkul, S. (2008) Effects of IL-17 on human gingival fibroblasts. J. Dent. Res. 87, 267-272.
DOI
ScienceOn
|
35 |
Kawanokuchi, J., Shimizu, K., Nitta, A., Yamada, K., Mizuno, T., Takeuchi, H. and Suzumura, A. (2008) Production and functions of IL-17 in microglia. J. Neuroimmunol. 194, 54-61.
DOI
ScienceOn
|
36 |
Beklen, A., Ainola, M., Hukkanen, M., Gurgan, C., Sorsa, T. and Konttinen, Y. T. (2007) MMPs, IL-1, and TNF are regulated by IL-17 in periodontitis. J. Dent. Res. 86, 347-351.
DOI
ScienceOn
|
37 |
Jovanovic, D. V., Di Battista, J. A., Martel-Pelletier, J., Jolicoeur, F. C., He, Y., Zhang, M., Mineau, F. and Pelletier, J. P. (1998) IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 160, 3513-3521.
|
38 |
Shahrara, S., Pickens, S. R., Mandelin, A. M. 2nd, Karpus, W. J., Huang, Q., Kolls, J. K. and Pope, R. M. (2010) IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J. Immunol. 184, 4479-4487.
DOI
ScienceOn
|
39 |
Barin, J. G., Baldeviano, G. C., Talor, M. V., Wu, L., Ong, S., Quader, F., Chen, P., Zheng, D., Caturegli, P., Rose, N. R. and Cihakova, D. (2012) Macrophages participate in IL-17-mediated inflammation. Eur. J. Immunol. 42, 726-736.
DOI
ScienceOn
|
40 |
Hosokawa, Y., Hosokawa, I., Ozaki, K., Nakanishi, T., Nakae, H. and Matsuo, T. (2009) Catechins inhibit CCL20 production in IL-17A-stimulated human gingival fibroblasts. Cell. Physiol. Biochem. 24, 391-396.
DOI
ScienceOn
|
41 |
Zhang, F., Tanaka, H., Kawato, T., Kitami, S., Nakai, K., Motohashi, M., Suzuki, N., Wang, C. L., Ochiai, K., Isokawa, K. and Maeno, M. (2011) Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie 93, 296-305.
DOI
ScienceOn
|
42 |
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., Martin, T. J. and Suda, T. (1999) IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345-1352.
DOI
ScienceOn
|
43 |
Zhang, F., Koyama, Y., Sanuki, R., Mitsui, N., Suzuki, N., Kimura, A., Nakajima, A., Shimizu, N. and Maeno, M. (2010) IL-17A stimulates the expression of inflammatory cytokines via celecoxib-blocked prostaglandin in MC3T3-E1 cells. Arch. Oral Biol. 55, 679-688.
DOI
ScienceOn
|
44 |
Van Bezooijen, R. L., Papapoulos, S. E. and Lowik, C. W. (2001) Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling? Bone 28, 378-386.
DOI
ScienceOn
|
45 |
Trajkovic, V., Stosic-Grujicic, S., Samardzic, T., Markovic, M., Miljkovic, D., Ramic, Z. and Mostarica Stojkovic, M. (2001) Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. J. Neuroimmunol. 119, 183-191.
DOI
ScienceOn
|
46 |
Van bezooijen, R. L., Farih-Sips, H. C., Papapoulos, S. E. and Lowik, C. W. (1999) Interleukin-17: A new bone acting cytokine in vitro. J. Bone Miner. Res. 14, 1513-1521.
DOI
ScienceOn
|
47 |
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., Tanaka, S., Kodama, T., Akira, S., Iwakura, Y., Cua, D. J. and Takayanagi, H. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 203, 2673-2682.
DOI
ScienceOn
|
48 |
Yago, T., Nanke, Y., Ichikawa, N., Kobashigawa, T., Mogi, M., Kamatani, N. and Kotake, S. (2009) IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J. Cell Biochem. 108, 947-955.
DOI
ScienceOn
|